RecruitingPhase 2NCT04006522

89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

An Exploratory Study of 89Zr-DFO-Atezolizumab ImmunoPET/CT in Patients With Locally Advanced or Metastatic Renal Cell Carcinoma

Sponsor

James Brugarolas

Enrollment

55 participants

Start Date

Oct 2, 2019

Study Type

INTERVENTIONAL

Conditions

Renal Cell Carcinoma

Summary

This is an exploratory clinical trial to assess the potential of 89Zr-DFO-Atezolizumab Positron Emission Tomography/Computed Tomography (PET/CT) scans in patients with locally advanced or metastatic renal cell carcinoma (RCC). This open label, nontherapeutic trial will test the correlation of 89Zr-DFO-Atezolizumab immunoPET/CT with programmed death-ligand 1 (PD-L1) expression and the response to immune checkpoint inhibitor therapy in patients with RCC. There will be two cohorts, one made up of patients with localized RCC who will undergo 89Zr-DFO-Atezolizumab PET/CT prior to nephrectomy and a second cohort of patients with metastatic RCC who will undergo 89Zr-DFO-Atezolizumab PET/CT prior to treatment with an immune checkpoint inhibitor.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new type of imaging scan — called immunoPET/CT — that uses a radioactive form of an immunotherapy drug (atezolizumab) to show where immune checkpoints are active in kidney tumors. The goal is to help doctors predict which patients are most likely to respond to immunotherapy. **You may be eligible if...** - You have suspected or confirmed kidney cancer (renal cell carcinoma) - You are planning to have surgery to remove your kidney, OR - You have metastatic kidney cancer and are about to start immunotherapy treatment - You are able to lie still for a 30–60 minute PET/CT scan **You may NOT be eligible if...** - You are unwilling or unable to provide informed consent - Your physical condition prevents you from completing the scan - You have already completed immunotherapy without surgical plans Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.